

Title (en)
THERAPEUTIC FORMULATIONS AND USES THEREOF

Title (de)
THERAPEUTISCHE FORMULIERUNGEN UND VERWENDUNGEN DAVON

Title (fr)
FORMULATIONS THÉRAPEUTIQUES ET LEURS UTILISATIONS

Publication
EP 4041245 A1 20220817 (EN)

Application
EP 20883598 A 20201029

Priority
• US 201962929631 P 20191101
• US 2020057899 W 20201029

Abstract (en)
[origin: WO2021087074A1] Provided herein are pharmaceutically acceptable compositions containing a selective cyclooxygenase-2 (COX-2) inhibitor (coxib) and optionally buprenorphine. In particular, compositions containing a coxib formulated for oral, topical or subcutaneous administration to treat pain or inflammation are described.

IPC 8 full level
A61K 31/60 (2006.01); **A61K 31/192** (2006.01); **A61K 31/415** (2006.01)

CPC (source: EP)
A61K 9/0014 (2013.01); **A61K 9/0019** (2013.01); **A61K 9/08** (2013.01); **A61K 9/2054** (2013.01); **A61K 31/352** (2013.01); **A61K 31/485** (2013.01); **A61K 47/10** (2013.01); **A61K 47/12** (2013.01); **A61P 29/00** (2018.01)

C-Set (source: EP)
1. **A61K 31/485** + **A61K 2300/00**
2. **A61K 31/352** + **A61K 2300/00**

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

DOCDB simple family (publication)
WO 2021087074 A1 20210506; AU 2020375825 A1 20220602; CA 3156590 A1 20210506; CN 114728014 A 20220708; CN 118750482 A 20241011; EP 4041245 A1 20220817; EP 4041245 A4 20231213; EP 4233854 A2 20230830; EP 4233854 A3 20240117; JP 2023501207 A 20230118

DOCDB simple family (application)
US 2020057899 W 20201029; AU 2020375825 A 20201029; CA 3156590 A 20201029; CN 202080079622 A 20201029; CN 202410884200 A 20201029; EP 20883598 A 20201029; EP 23174724 A 20201029; JP 2022525194 A 20201029